

DAFTAR PUSTAKA

- Bartosikova L dan Necas J. 2018. Epigallocatechin gallate: a review. *Veterinarni Medicina*, 63, 2018 (10): 443–467 Review Article <https://doi.org/10.17221/31/2018-VETMED>.
- Behbehani, J. M., Irshad, M., Shreaz, S., & Karched, M. (2019). Synergistic effects of tea polyphenol epigallocatechin 3-O-gallate and azole drugs against oral *Candida* isolates. *Journal de Mycologie Médicale*. doi:10.1016/j.mycmed.2019.01.011
- Berberi, A., Noujeim, Z., & Aoun, G. (2015). Epidemiology of Oropharyngeal Candidiasis in Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Patients and CD4+ Counts. *Journal of international oral health : JIOH*, 7(3), 20–23.
- Binder, U, Aigner, M, Risslegger, B, Hörtnagl, C, Lass-Flörl, C, Lackner, M 2019, ‘Minimal inhibitory concentration (MIC)-Phenomena in *Candida albicans* and their impact on the diagnosis of antifungal resistance’, *Journal of Fungi*, 5.
- Castellote, LC & Soriano, YJ 2013, ‘Clinical and microbiological diagnosis of oral candidiasis’, *J Clin Exp Dent*, 5(5):e279-86.
- Chai, ZY, Li, XM, Liang, JP, Xiang, LP, Wang, KR, Shi, YL, Yang, R, Shi M, Ye, JH, Lu, JL, Zheng, XQ, Lian, YR 2018, ‘Bioavailability of tea catechins and its improvement’, *Molecules*, 23(2436).
- Cuesta, CG, Perez, MGS & Bagan, JV 2014, ‘Current treatment of oral candidiasis: A literature review’, *J Clin Exp Dent*, 6(5): e576-e582.
- Dewi, ISL. dan Hidayati, A. N 2015, ‘Manifestasi Kelainan Kulit pada Pasien HIV & AIDS’, *Berkala Ilmu Kesehatan Kulit dan Kelamin*, 27(2), hal. 97– 105.
- Granja, A, Pinheiro, M & Sallette-Reis 2016, ‘Epigallocatechin gallate nanodelivery systems for cancer therapy’, *Nutrients*, 8(5):307.
- Granja A, Frias I, Neves I, Neves AR, Pinheiro M dan Reis S. 2017. Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems. *Hindawi BioMed Research International* 2017:5813793;15 pages <https://doi.org/10.1155/2017/5813793>
- Guida, A, Lucchese, A, Minervini, G, De Gregoria, V, Coretti, L, Grimaldi, E, Minervini, D, Serpico, R, Donnaruma, G 2013, ‘In vitro analysis of antifungal activity of epigallocatechin-gallate: preliminary study’, *European Journal of Inflammation*, 11(3): 911-917.
- Heron, SE & Elahi, S 2017, ‘HIV infection and compromised mucosal immunity: Oral manifestations and systemic inflammation’, *Front Immunol*, 8:241.
- Hirasawa, M & Takada, K 2004, ‘Multiple effects of green tea catechin on the antifungal activity of antimycotics against *Candida albicans*’, *Journal of Antimicrobial Chemotherapy*, 53, 225–229.

- Jacob, R & Konnikov, N 2012 'Oral antifungal agents' di Goldsmith LA, et al. Fitzpatrick's Dermatology in General Medicine. Edisi ke-8. New York: McGraw Hill, 2796–2806.
- Jahani S. et al. 2017. Antifungal Effect Of The Extract Of The Plants Against Candida Albicans. *Int J Infect*, vol 4, no 2, pp. 1–4.
- James, WD, Berger, TG, Elston, DM, Andrews, GC 2011, *Andrews' Diseases of The Skin : Clinical Dermatology*, edisi ke-11, Elsevier, Philadelphia, hal. 287-322
- Jayachandran, AL, Katragadda, R, Ravinder, T, Vajravelu, L, Manorajan, L, Hemalatha, S, Shanugam, K 2018, 'Antifungal susceptibility pattern among candida species: an evaluation of disc diffusion and broth micro-dilution method', *J Microbiol Infect Dis*, 8(3):97-101
- Khalandi, H, Masoori, L, Farahyar, S, Delbandi, AA, Raiesi, O, Farzanegan, A, Khalandi, G, Mahmoudi, S, Erfanirad, T, Falahati, M 2020, 'Antifungal Activity of Capric Acid, Nystatin, and Fluconazole and Their In Vitro Interactions Against Candida Isolates from Neonatal Oral Thrush', *Assay and Drug Development Technologies*, 18(3):1-7
- Lockhart, SR, Iqbal, N, Cleveland, AA, Farley, MM, Harrison, LH, Bolden, CB, Baughman, W, Stein, B, Hollick, R, Park, BJ, Chiller, T 2012, 'Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011', *Journal of Clinical Microbiology*, 50(11): 3435–3442.
- Madhura, MG, Shweta, RD, Kumar, BV, Savithri, D, Gajalakshmi, S Soumya, BV 2016, 'Antifungal effect of green tea extracts on oral Candida species: An in vitro study', *Journal of Advanced Clinical and Research Insight*, 3:1-4.
- Maharani, CS, Murtiastutik, D, Rahmadewi 2018, 'Uji resistensi spesies candida terhadap obat nistatin, ketokonazol, dan flukonazol pada pasien kandidiasis oral dengan hiv/aids menggunakan metode disc diffusion', tesis Doktor, Universitas Airlangga, Surabaya
- Marak, MB & Dhanashree, B 2018, 'Antifungal susceptibility and biofilm production of Candida spp. isolated from clinical samples', *International Journal of Microbiology*, 7495218.
- Matsumoto, Y., Kaihatsu, K., Nishino, K., Ogawa, M., Kato, N., & Yamaguchi, A. (2012). Antibacterial and antifungal activities of new acylated derivatives of epigallocatechin gallate. *Frontiers in microbiology*, 3, 53. <https://doi.org/10.3389/fmicb.2012.00053>
- Mereles, D & Hunstein, W 2011, 'Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?', *Int J Mol Sci*, 12(9):5592-5603.
- Moges, B, Bitew, A, Shewaamare, A 2016, 'Spectrum and the in vitro antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis', *International Journal of Microbiology*, 3037817:1-8.

- Mollashahi F, N., Bokaeian, M., Farhad Mollashahi, L., & Afrougheh, A. (2015). Antifungal Efficacy of Green Tea Extract against *Candida Albicans* Biofilm on Tooth Substrate. *Journal of dentistry (Tehran, Iran)*, 12(8), 592–598.
- Murtiastutik D, Maharani CS, Rahmadewi R. 2019. Profile of *Candida* Resistancy to Fluconazole in Male Patient with Oral Candidiasis in HIV/AIDS. *J of AIDS & Clin Res*, vol 10, no 1, pp. 1-6.
- Murtiastutik, D. et al. 2019. Nistatin Profile on *Candida* Species in HIV / AIDS 89 Patients with Oral Candidiasis : A Phenomenology Study. *J Pure Appl microbiol*, vol 13, no 4, pp. 2013–2019.
- Naif, HM 2013, 'Pathogenesis of HIV infection', *Infect Dis Rep*, 5(Suppl 1): e6.
- Namita, P, Mukesh, R, Vijay, KJ 2012, 'Camellia Sinesis (Green tea): A Review', *Global Journal of Pharmacology*, 6 (2): 52-59.
- Nanteza, M, Tusiime, JB, Kalyango, J, Kasangaki, A 2014, ' Association between oral candidiasis and low CD4+ count among HIV positive patients in Hoima Regional Referral Hospital', *BMC Oral Health*, 14:143
- Nenoff, P, Kruer, C, Neumeister, C, Schwantes, U, Koch, D 2016, 'In vitro susceptibility testing of yeast to nystatin-low minimum inhibitory concentrations suggest no indication of in vitro resistance of *Candida albicans*, *Candida* species or non-*Candida* yeast species to nystatin', *Clin Med Invest*, 1(3):71-76
- Nosratzahi, T, Nosratzahi, M, Nosratzahi, S, Lotfi, F 2019, 'The comparison of the effect of curcumin with nystatin on inhibition level of *Candida albicans*', *Journal of Experimental Pharmacology*, 11:93-97
- Nugraha AP et al. 2018. Prevalence of *Candida* species in oral candidiasis and correlation with CD4+ count in HIV/AIDS patients at Surabaya, Indonesia. *Journal of International Dental and Medical Research* 11(1):81-85
- Nur'aeny, N, Hidayat, W, Dewi, TS, Herawati, E & Wahyuni, IS 2017, 'Profil oral candidiasis di bagian ilmu penyakit mulut RSHS Bandung periode 2010-2014', *Majalah Kedokteran Gigi Indonesia* 3(1):23-8.
- Park, B. J., Taguchi, H., Kamei, K., Matsuzawa, T., Hyon, S. H., & Park, J. C. (2011). In vitro antifungal activity of epigallocatechin 3-O-gallate against clinical isolates of dermatophytes. *Yonsei medical journal*, 52(3), 535–538. <https://doi.org/10.3349/ymj.2011.52.3.535>
- Patel PK, Erlandsen JE, Kirkpatrick JE dan Berg DK, et al. 2012. The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy. *AIDS Research and Treatment*. Volume 2012 Article ID; 262471: 5 pages <https://doi.org/10.1155/2012/262471>
- Patil, S, Rao, RS, Majumdar, B, Anil, S 2015, 'Clinical appearance of oral *Candida* infection and therapeutic strategies', *Front Microbiol*, 6:1391.

- Patil, S., Majumdar, B., Sarode, S. C., Sarode, G. S., & Awan, K. H. (2018). Oropharyngeal Candidosis in HIV-Infected Patients-An Update. *Frontiers in microbiology*, 9, 980. <https://doi.org/10.3389/fmicb.2018.00980>
- Perlin, DS, Rautemaa-Richardson, R, Alastruey-Izquierdo, A 2017, 'The global problem of antifungal resistance: prevalence, mechanisms, and management', *The Lancet Infectious Diseases*, (12):e383-e392
- Pfaller, M 2017, 'Antifungal susceptibility testing', In TW, Post (ed.), *UpToDate*. Waltham, MA: UpToDate.
- Prasad, R, Banerjee, A, Shah, AH 2017, 'Resistance to antifungal therapies', *Essays in Biochemistry*, 61(1):157-166
- Putranti, A 2018, 'Oral candidiasis as clinical manifestation of HIV/AIDS infection in Airlangga University hospital patients', *IOP Conf. Series: Earth and Environmental Science*, 125:012063.
- Rahayu, RP, Prasetyo, RA, Purwanto, DA, Kresnodi, U, Iskandar, RPD, Rubianto, M 2018, 'The immunomodulatory effect of green tea (*Camellia sinensis*) leaves extract on immunocompromised Wistar rats infected *Candida albicans*', *Veterinary World*, 11(5):765-70.
- Reza NR, Sugiman T, Basuki S. 2017. Uji kepekaan in vitro flukonazol terhadap spesies *Candida* penyebab kandidiasis oral pada pasien HIV/AIDS dengan Vitek II. *BIKKK*, vol. 29, no. 3, pp. 234-42.
- Sato, T., Kishi, M., Suda, M. et al. Prevalence of *Candida albicans* and non-*albicans* on the tongue dorsa of elderly people living in a post-disaster area: a cross-sectional survey. *BMC Oral Health* 17, 51 (2017). <https://doi.org/10.1186/s12903-017-0342-0>
- Singh, BN, Shankar, S & Srivastava, RK 2011, 'Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications', *Biochem Pharmacol*, 82(12):1807-1821.
- Singh, A., Verma, R., Murari, A., & Agrawal, A. (2014). Oral candidiasis: An overview. *Journal of oral and maxillofacial pathology : JOMFP*, 18(Suppl 1), S81-S85. <https://doi.org/10.4103/0973-029X.141325>
- Spalanzani, Regiane Nogueira, Mattos, Karine, Marques, Luiza Inahe, Barros, Pedro Fernando Diniz, Pereira, Pamela Iruama Peres, Paniago, Anamaria Mello Miranda, Mendes, Rinaldo Poncio, & Chang, Marilene Rodrigues. (2018). Clinical and laboratorial features of oral candidiasis in HIV-positive patients. *Revista da Sociedade Brasileira de Medicina Tropical*, 51(3), 352-356. <https://doi.org/10.1590/0037-8682-0241-2017>
- Spampinato, C & Leonardi, D 2013, 'Candida infections, causes, targets, and resistance mechanisms: Traditional and alternative antifungal agents', *Biomed Res Int*, 2013:204237.
- Suryana K, Suharsono H, Antara IG PJ. Factors Associated with Oral Candidiasis in People Living with HIV/AIDS: A Case Control Study. *HIV AIDS (Auckl)*. 2020;12:33-39 <https://doi.org/10.2147/HIV.S236304>
- Steinmann, J., Buer, J., Pietschmann, T., & Steinmann, E. (2013). Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component

- of green tea. *British journal of pharmacology*, 168(5), 1059–1073.
<https://doi.org/10.1111/bph.12009>
- Suyoso, S, Ervianty, E, Barakbah, J, 2014 ‘Kandidiasis Mukosa’, dalam Suyoso S, Ervianti E, B. J. (ed.) *Panduan praktik klinis SMF Ilmu Kesehatan Kulit dan Kelamin RSUD Dr. Soetomo*. Surabaya, hal. 95–97.
- Thatai, P, Sapra, B 2016, ‘Critical review on retrospective and prospective changes in antifungal susceptibility testing for dermatophytes’, *Mycoses*, 59(10):615-27
- Verweij, PE, Chowdhary, A, Melchers, WJG, Meis, JF 2016, ‘Azole resistance in aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles?’, *Clinical Infectious Diseases*, 62(3): 362–368
- Walangare T, Hidayat T, Basuki S. 2014. *Profil Spesies Candida pada Pasien Kandidiasis oral dengan infeksi HIV & AIDS Berkala Ilmu Kesehatan Kulit Kelamin*, vol. 26, no. 1, pp. 1-7.
- Wang, Y, Bandara, HMHN, Mikkelsen, D, Samaranayake, LP 2017, ‘Effects of tea extracts on the colonization behaviour of Candida species: attachment inhibition and biofilm enhancement’, *Journal of Medical Microbiology*, 66:1244-52.
- Warrier, SA & Sathasivasubramanian, S 2015, ‘Human immunodeficiency virus induced oral candidiasis’, *Journal of Pharmacy and Bioallied Sciences*, 7(Suppl 2):S812-4.
- Wolff, K, Johnson, R, Saavedra, AP 2013, ‘Oropharyngeal Candidiasis’, *Fitzpatrick Color Atlas and Synopsis of Clinical Dermatology*, hal. 594-596
- Yassin, MT, Mostafa, AA, Al-Askar, AA, Bdeer, R 2020, ‘In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis’, *European Journal of Medical Research*, 25(1): 1-9